Log in
Sign up
Golden has been acquired by ComplyAdvantage.Read about it here ⟶
‌

US Patent 8188231 Optimized FC variants

Patent 8188231 was granted and assigned to Xencor on May, 2012 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributorsActivity
Is a
Patent
Patent
Current Assignee
Xencor
Xencor
Date Filed
May 5, 2005
Date of Patent
May 29, 2012
Patent Application Number
11124620
Patent Citations Received
‌
US Patent 12122840 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
0
‌
US Patent 11919935 Ultra-long acting insulin-Fc fusion proteins and methods of use
0
‌
US Patent 12084513 Anti-C1S antibodies and methods of use
0
‌
US Patent 12116414 Method of modifying isoelectric point of antibody via amino acid substitution in CDR
0
‌
US Patent 11667689 Insulin-Fc fusion proteins and methods of use to treat cancer
0
‌
US Patent 11673934 Ultra-long acting insulin-Fc fusion proteins and methods of use
0
‌
US Patent 11673945 Bispecific antigen binding proteins
0
‌
US Patent 11773151 Ultra-long acting insulin-Fc fusion proteins and methods of use
‌
US Patent 11780912 Composition for prophylaxis or treatment of IL-8 related diseases
‌
US Patent 11891434 Antigen-binding molecule capable of binding to plurality of antigen molecules repeatedly
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
Patent Number
8188231
Patent Primary Examiner
‌
Chun Dahle

Find more entities like US Patent 8188231 Optimized FC variants

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo